<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5155">
  <stage>Registered</stage>
  <submitdate>31/08/2015</submitdate>
  <approvaldate>31/08/2015</approvaldate>
  <nctid>NCT02547922</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis</studytitle>
    <scientifictitle>A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis</scientifictitle>
    <utrn />
    <trialacronym>TULIP-LN1</trialacronym>
    <secondaryid>D3461C00007</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lupus Nephritis</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Anifrolumab
Treatment: drugs - Placebo

Experimental: Anifrolumab - Lower Dose - Anifrolumab - Lower Dose

Experimental: Anifrolumab - Higher Dose - Anifrolumab - Higher Dose

Placebo Comparator: Placebo - Placebo IV Q4W plus SOC


Other interventions: Anifrolumab
Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112

Treatment: drugs: Placebo
Administration administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Relative difference in change from baseline in 24-hour urine protein to creatinine ratio (UPCR)</outcome>
      <timepoint>From Week 1 (baseline) to Week 52</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Difference in the proportion of subjects achieving the composite endpoint Complete Renal Response (CRR) - CRR is defined as meeting all of the following:
Estimated glomerular filtration rate (eGFR) is
=80 mL/min/1.73 m2, if baseline eGFR was =90 mL/min/1.73 m2 or
&gt;85% of baseline eGFR, if baseline eGFR was &lt;90 mL/min/1.73 m2
24-hour UPCR&lt;0.5 mg/mg (please, note that the units are were changed from gm/gm to mg/mg, and will be updated in a future protocol amendment)
No discontinuation of investigational product or use of restricted medication beyond the protocol-allowed threshold before assessment</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Difference in the proportion of subjects achieving the composite endpoint Alternative Complete Renal Response (aCRR) - aCRR is defined as meeting all of the following:
Estimated glomerular filtration rate (eGFR) is
=80 mL/min/1.73 m2, if baseline eGFR was =90 mL/min/1.73 m2 or
&gt;85% of baseline eGFR, if baseline eGFR was &lt;90 mL/min/1.73 m2
24-hour UPCR&lt;0.5 mg/mg (please, note that the units are were changed from gm/gm to mg/mg, and will be updated in a future protocol amendment)
No discontinuation of investigational product or use of restricted medication beyond the protocol allowed threshold before assessment
Inactive urine sediment (defined as &lt;10 RBC/hpf)</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Events - Including AEs of special interest [AESIs].</outcome>
      <timepoint>Week 0-52</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Main 

          1. Age 18 through 70 years at the time of screening

          2. Fulfils at least 4 of the 11 criteria of the revised 1982 ACR classification criteria
             for SLE, at least one of which must be:

               1. Positive antinuclear antibody (ANA) test (1:40 or higher) or

               2. Elevated anti-dsDNA antibodies at screening (reported as equivocal or positive
                  results), as per the centrallaboratory; or

               3. Anti-Smith antibody at screening elevated to above normal (ie, positive or
                  equivocal results) as per the central laboratory

          3. Class III (±Class V) or Class IV (±Class V) LN according to the World Health
             Organisation (WHO) or 2003 ISN/RPS classification based on a renal biopsy obtained
             within 12 weeks prior to signing the ICF or during the screening period:

          4. Urine protein to creatinine ratio &gt;1 gm/gm (113.17 mg/mmol), obtained on a 24-hour
             urine collection at screening

          5. Estimated glomerular filtration rate =35 mL/min/1.73 m2

          6. Must not have active or latent TB on either chest radiograph or by Quantiferon gold
             test

          7. Women of childbearing potential must have a negative serum beta-hCG test at screening
             and negative urine pregnancy test prior to the first dose of sponsor-provided MMF.

        Main</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Receipt of any investigational product (small molecule or biologic) or commercially
             available biologic agent within four weeks or 5 half lives prior to signing of the
             ICF, whichever is greater

          2. Pure Class V membranous LN on a renal biopsy obtained within 12 weeks prior to signing
             ICF or during the screening period

          3. Known intolerance to =1.0 gm/day of MMF

          4. History of dialysis within 12 months prior to signing the ICF or expected need for
             renal replacement therapy (dialysis or renal transplant) within a 6 month period after
             enrolment

          5. Subjects, who at the time of signing the ICF, received any of the following
             immunosuppressive therapies after their qualifying biopsy (b) Oral corticosteroids
             &gt;0.5 mg/kg/day for more than 8 weeks or (c) Oral or IV pulse methylprednisolone &gt;3.0
             gm (cumulative dose) or (d) IV cyclophosphamide &gt;2 pulses of high-dose (=0.5 gm/m2) or
             &gt;4 doses of low dose (500 mg every 2 weeks) or (e) Average MMF &gt;2.5 gm/day (&gt;1800
             mg/day of enteric-coated mycophenolate sodium) for more than 8 weeks or (f) Tacrolimus
             &gt;4 mg/day for more than 8 weeks

          6. Major surgery within 8 weeks before signing the ICF or major surgery planned during
             the study period

          7. History of any non-SLE disease that has required treatment with oral or parenteral
             corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to
             signing the ICF

          8. Confirmed positive test for hepatitis B or hepatitis C

          9. Any severe herpes infection at any time prior to randomization

         10. Opportunistic infection requiring hospitalisation or parenteral antimicrobial
             treatment within 3 years prior to randomization (vaginal, oral and skin candidiasis is
             not an exclusionreason).

         11. History of cancer, apart from:

               1. Squamous or basal cell carcinoma of the skin that has been successfully treated

               2. Cervical cancer in situ that has been successfully treated</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>4/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>20/07/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Adelaide</hospital>
    <hospital>Research Site - Clayton</hospital>
    <hospital>Research Site - Herston</hospital>
    <hospital>Research Site - Liverpool BC</hospital>
    <hospital>Research Site - Parkville</hospital>
    <hospital>Research Site - Westmead</hospital>
    <hospital>Research Site - Woolloongabba</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>VIC 3168 - Clayton</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>1871 - Liverpool BC</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels (Jette)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 14</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Etienne Cedex 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kaposvár</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pécs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gwangju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Chihuahua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>San Luis Potosí</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Arequipa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kraków</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lódz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Orenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Samara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Nis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Bilbao</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Parexel</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment
      regimen of two doses of anifrolumab versus placebo in adult subjects with active
      proliferative lupus nephritis (LN).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02547922</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>AstraZeneca AB</name>
      <address>AstraZeneca</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>AstraZeneca Clinical Study Information Center</name>
      <address />
      <phone>1-877-240-9479</phone>
      <fax />
      <email>information.center@astrazeneca.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>